BACKGROUND: The Flutter(®)VRP1 combines high frequency oscillation and positive expiratory pressure (PEP). OBJECTIVE: To separately evaluate the effect of the Flutter(®)VRP1 components (high frequency oscillation and PEP) on mucus transportability in patients with bronchiectasis. METHODS:Eighteen patients with bronchiectasis received sessions with the Flutter(®)VRP1 or PEP for 30 min daily in a randomized, crossover study. The treatment duration was four weeks with one of the therapies, one week of a "wash-out" period and followed by four more weeks with the other treatment. Weekly secretion samples were collected and evaluated for mucociliary relative transport velocity (RTV), displacement in a simulated cough machine (SCM) and contact angle measurement (CAM). For the proposed comparisons, a linear regression model was used with mixed effects with a significance level of 5%. RESULTS: The Flutter(®)VRP1 treatment resulted in greater displacement in SCM and lower CAM when comparing results from the first (9.6 ± 3.4 cm and 29.4 ± 5.7°, respectively) and fourth weeks of treatment (12.44 ± 10.5 cm and 23.28 ± 6.2°, respectively; p < 0.05). There was no significant difference in the RTV between the treatment weeks for either the Flutter(®)VRP1 or PEP. CONCLUSION: The use of the Flutter(®)VRP1 for four weeks is capable of altering the respiratory secretion transport properties, and this alteration is related to the high frequency oscillation component.
RCT Entities:
BACKGROUND: The Flutter(®)VRP1 combines high frequency oscillation and positive expiratory pressure (PEP). OBJECTIVE: To separately evaluate the effect of the Flutter(®)VRP1 components (high frequency oscillation and PEP) on mucus transportability in patients with bronchiectasis. METHODS: Eighteen patients with bronchiectasis received sessions with the Flutter(®)VRP1 or PEP for 30 min daily in a randomized, crossover study. The treatment duration was four weeks with one of the therapies, one week of a "wash-out" period and followed by four more weeks with the other treatment. Weekly secretion samples were collected and evaluated for mucociliary relative transport velocity (RTV), displacement in a simulated cough machine (SCM) and contact angle measurement (CAM). For the proposed comparisons, a linear regression model was used with mixed effects with a significance level of 5%. RESULTS: The Flutter(®)VRP1 treatment resulted in greater displacement in SCM and lower CAM when comparing results from the first (9.6 ± 3.4 cm and 29.4 ± 5.7°, respectively) and fourth weeks of treatment (12.44 ± 10.5 cm and 23.28 ± 6.2°, respectively; p < 0.05). There was no significant difference in the RTV between the treatment weeks for either the Flutter(®)VRP1 or PEP. CONCLUSION: The use of the Flutter(®)VRP1 for four weeks is capable of altering the respiratory secretion transport properties, and this alteration is related to the high frequency oscillation component.
Authors: Rocio Martín-Valero; Ana Maria Jimenez-Cebrian; Jose A Moral-Munoz; Maria de-la-Casa-Almeida; Manuel Rodriguez-Huguet; Maria Jesus Casuso-Holgado Journal: J Clin Med Date: 2020-01-15 Impact factor: 4.241
Authors: Ada Clarice Gastaldi; Paolo Paredi; Anjana Talwar; Sally Meah; Peter J Barnes; Omar S Usmani Journal: Medicine (Baltimore) Date: 2015-10 Impact factor: 1.817